<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1002" relname="span">The number of males diagnosed with prostate cancer</segment>
<segment id="2" parent="1" relname="elaboration">( PCa )</segment>
<segment id="3" parent="1001" relname="same_unit">is increasing all over the world .</segment>
<segment id="4" parent="1003" relname="joint">Most patients with early-stage PCa can be treated by the appropriate therapy , such as radical prostatectomy or irradiation .</segment>
<segment id="5" parent="1007" relname="span">On the other hand , androgen deprivation therapy</segment>
<segment id="6" parent="5" relname="restatement">( ADT )</segment>
<segment id="7" parent="1006" relname="same_unit">is the standard systemic therapy</segment>
<segment id="8" parent="1006" relname="elaboration">given to patients with advanced PCa .</segment>
<segment id="9" parent="1010" relname="concession">ADT induces temporary remission ,</segment>
<segment id="10" parent="1011" relname="span">but the majority of patients</segment>
<segment id="11" parent="10" relname="elaboration">( approximately 60 % )</segment>
<segment id="12" parent="1013" relname="span">eventually progress to castration-resistant prostate cancer</segment>
<segment id="13" parent="12" relname="elaboration">( CRPC ) ,</segment>
<segment id="14" parent="1013" relname="elaboration">which is associated with a high mortality rate .</segment>
<segment id="15" parent="1015" relname="span">Generally , well-differentiated PCa cells are androgen-dependent ,</segment>
<segment id="16" parent="1017" relname="span">i. e. , androgen receptor</segment>
<segment id="17" parent="16" relname="restatement">( AR )</segment>
<segment id="18" parent="1016" relname="same_unit">signaling regulates cell cycle and differentiation .</segment>
<segment id="19" parent="1019" relname="span">Loss of AR signaling</segment>
<segment id="20" parent="21" relname="circumstance">after ADT triggers androgen-independent outgrowth ,</segment>
<segment id="21" parent="1020" relname="span">generating poorly differentiated , uncontrollable PCa cells .</segment>
<segment id="22" parent="1023" relname="circumstance">Once PCa cells lose their sensitivity to ADT ,</segment>
<segment id="23" parent="1024" relname="background">effective therapies are limited .</segment>
<segment id="24" parent="1025" relname="span">In the last few years , however , several new options for the treatment of CRPC have been approved ,</segment>
<segment id="25" parent="24" relname="elaboration">e. g. , the CYP17 inhibitor , the AR antagonist , and the taxane .</segment>
<segment id="26" parent="1028" relname="concession">Despite this progress in the development of new drugs ,</segment>
<segment id="27" parent="1028" relname="span">there is a high medical need</segment>
<segment id="28" parent="27" relname="elaboration">for optimizing the sequence and combination of approved drugs .</segment>
<segment id="29" parent="1031" relname="span">Thus , identification of predictive biomarkers may help in the context of personalized medicine</segment>
<segment id="30" parent="29" relname="purpose">to guide treatment decisions ,</segment>
<segment id="31" parent="1032" relname="joint">improve clinical outcomes ,</segment>
<segment id="32" parent="1032" relname="joint">and prevent unnecessary side effects .</segment>
<segment id="33" parent="1035" relname="span">Departments of Nephro-Urologic Surgery and Andrology</segment>
<segment id="34" parent="33" relname="elaboration">( Professor Emeritus Yoshiki Sugimura )</segment>
<segment id="35" parent="1037" relname="span">and Oncologic Pathology</segment>
<segment id="36" parent="35" relname="elaboration">( Professor Emeritus Taizo Shiraishi ) ,</segment>
<segment id="37" parent="1036" relname="same_unit">Mie University Graduate School of Medicine , organized the semi-closed symposium on Biology of Prostate Gland Ise-Shima .</segment>
<segment id="38" parent="1038" relname="joint">This symposium was started in 2002</segment>
<segment id="39" parent="1040" relname="span">and was held every four years in 2006 , 2010 , 2014 , and 2018</segment>
<segment id="40" parent="39" relname="manner">without any financial support from pharmaceutical companies and chemical industries .</segment>
<segment id="41" parent="1041" relname="joint">Each year , the symposium was attended by 40 â€“ 50 Japanese investigators with expertise and interest in biology of the prostate gland and PCa .</segment>
<segment id="42" parent="1044" relname="span">The goal of this symposium was to discuss the biological mechanism of the development and progression of prostatic proliferative diseases such as benign prostatic hyperplasia</segment>
<segment id="43" parent="42" relname="restatement">( BPH )</segment>
<segment id="44" parent="1043" relname="joint">and PCa .</segment>
<segment id="45" parent="1046" relname="joint">Several major topic areas were discussed ,</segment>
<segment id="46" parent="1046" relname="joint">e. g. , the pathophysiology of BPH , the tumor microenvironment of PCa , AR signaling in PCa progression , and the development of PCa detection and diagnosis .</segment>
<segment id="47" parent="1047" relname="span">This Special Issue includes the major topics</segment>
<segment id="48" parent="47" relname="elaboration">discussed at the symposium in 2018 .</segment>
<segment id="49" parent="1049" relname="span">In this Special Issue , we focused on cytobiology of human PCa cells and its clinical applications</segment>
<segment id="50" parent="1050" relname="span">to develop a major step towards personalized medicine</segment>
<segment id="51" parent="50" relname="elaboration">matched to the individual needs of patients with early-stage and advanced PCa and CRPC .</segment>
<segment id="52" parent="53" relname="attribution">We hope</segment>
<segment id="53" parent="1051" relname="span">that this Special Issue attracts a lot of attention for readers with expertise and interest in the cytobiology of human PCa cells and its clinical applications .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1003" relname="preparation"/>
<group id="1002" type="span" parent="1001" relname="same_unit"/>
<group id="1003" type="multinuc" parent="1000" relname="span"/>
<group id="1005" type="span" parent="1003" relname="joint"/>
<group id="1006" type="multinuc" parent="1005" relname="span"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1009" type="span" parent="1003" relname="joint"/>
<group id="1010" type="multinuc" parent="1009" relname="span"/>
<group id="1011" type="span" parent="1010" relname="same_unit"/>
<group id="1012" type="span" parent="1010" relname="same_unit"/>
<group id="1013" type="span" parent="1012" relname="span"/>
<group id="1015" type="span" parent="1003" relname="joint"/>
<group id="1016" type="multinuc" parent="15" relname="elaboration"/>
<group id="1017" type="span" parent="1016" relname="same_unit"/>
<group id="1019" type="span" parent="1003" relname="joint"/>
<group id="1020" type="span" parent="19" relname="circumstance"/>
<group id="1022" type="span" parent="1003" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1024" type="span" parent="1023" relname="span"/>
<group id="1025" type="span" parent="1024" relname="span"/>
<group id="1026" type="multinuc" parent="1025" relname="concession"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="span"/>
<group id="1029" type="span" parent="1026" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="span"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="multinuc" parent="1030" relname="same_unit"/>
<group id="1033" type="span" parent="1030" relname="elaboration"/>
<group id="1034" type="multinuc" parent="1033" relname="span"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1034" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="same_unit"/>
<group id="1038" type="multinuc" parent="1034" relname="evidence"/>
<group id="1039" type="span" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="span"/>
<group id="1041" type="multinuc" parent="1040" relname="elaboration"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="span"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1043" relname="elaboration"/>
<group id="1046" type="multinuc" parent="1045" relname="span"/>
<group id="1047" type="span" parent="1046" relname="evaluation"/>
<group id="1048" type="multinuc" parent="1003" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="sequence"/>
<group id="1050" type="span" parent="49" relname="purpose"/>
<group id="1051" type="span" parent="1048" relname="sequence"/>
	</body>
</rst>
